Table 4

Temporal timing of antithrombotics and venous thromboembolic events by patient

PatientVTETiming of antithrombotic and venous thromboembolic events
Full
3N/AHD 1 PPX enox, HD1–5 FD hep (HD 6–10 ASA 325), HD 5–10 PPX enox, 10–12 and 14–16 FD hep (HD 12–14 FD enox), HD 16-20 FD apix; LOS 20 days
5N/AHD 2–4 PPX hep (HD 2–5 ASA), HD 4–6 FD hep, 7–9 FD enox, 10–16 FD dabigatran; LOS 16 days
14N/AHD 4–8 PPX hep, HD 12–19 FD hep; LOS 19 days
18N/AHD 3–4 PPX hep, HD 4–5 FD warfarin, HD 6–11 FD enox; LOS 11 days
Prophylactic with concomitant antiplatelet
1N/AHD 9–44 PPX hep (HD 15–35 ASA), HD 44–46 FD hep (our HD 9), HD 52–71 PPX enox (HD 55–71 ASA), HD 1 IVC-F; LOS 71 days
6N/AHD 3–20 PPX enox with ASA; LOS 20 days
7N/AHD 1–7 PPX enox with ASA; LOS 7 days
10N/AHD 4–26 PPX dalteparin (HD 4–26 ASA 325); LOS 26 days
11N/AHD 4–12 FD hep, HD 24–54 PPX dalteparin (HD18-54 ASA 325); LOS 54 days
12N/AHD 3–8 PPX dalteparin (HD 4–6 ASA suppository, HD 7–8 ASA 325); LOS 8 days
16N/AHD 3–18 PPX hep (HD 17–18 ASA 325); LOS 18 days
214 PEHD 2–4 PPX enox (HD 2–4 ASA suppository), HD 4–20 FD enox (HD 4–23 ASA 325), HD 20–23 FD apix; LOS 23 days
2211 DVTHD 2–19 PPX hep (HD 3–25 ASA 81), HD 19–33 FD hep, HD 34–44 PPX hep, HD 44–46 PPX enox, HD 12 IVC-F; LOS 59
2510 DVTHD 3–7 PPX hep (HD 4–51 ASA 81), HD 8–11 PPX dalteparin, HD 11–51 FD dalteparin, HD 31–51 warfarin (took a while for INR to become therapeutic); LOS 51 days
Prophylactic anticoagulation
2N/AHD 2–48 PPX hep (HD 6–10 ASA), HD 48–58 PPX enox; LOS 58 days
4N/AHD 0–6 PPX enox; LOS 6 days
8N/AHD 3–9 PPX enox; LOS 9 days
9N/AHD 1–125 PPX hep (HD 3–22 ASA suppository); LOS 125 days
195 DVT, 23 PEHD 3–5 PPX enox, HD 5–11 PPX hep (HD 7–9 ASA suppository, HD 10–28 ASA 325), HD 12–28 PPX enox, HD 29 FD hep, HD 30–77 FD enox; LOS 77
205 DVTHD 2–5 PPX hep, HD 5–9 FD hep, HD 9–10 PPX hep, HD 10 IVC-F; LOS 17
237 DVT, 8 PEHD 3–4 PPX hep, HD 4–8 PPX enox, HD 8–9 FD hep, HD 9–34 FD enox, HD 32–34 warfarin, HD 9 IVC-F; LOS 34 days
243 DVTHD 2–3 PPX hep, HD 3–36 FD hep, HD 34–44 warfarin; LOS 44 days
No antithrombotics
13N/ANo antithrombotics; LOS 3
15N/ANo antithrombotics; LOS 41 days
171 DVTHD 3–4 PPX hep, HD 4–24 FD hep, HD 24–30 FD enox, HD 30–37 FD hep, HD 38–54 FD enox, HD 54 dalteparin; LOS 54 days
2611 PE, 19 DVTHD 3–8 PPX hep, HD 8–10 FD hep, HD 14–29 FD hep, HD 11 IVC-F; LOS 34 days
  • apix, apixaban; ASA, aspirin; DVT, deep vein thrombosis; enox, enoxaparin; FD, full dose; HD, hospital day; hep, heparin; INR, international normalized ratio; IVC-F, inferior vena cava filter; LOS, length of stay; N/A, not applicable; PE, pulmonary embolism; PPX, prophylactic dose; VTE, venous thromboembolism.